Compare VOC & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOC | CING |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 40.5M |
| IPO Year | N/A | N/A |
| Metric | VOC | CING |
|---|---|---|
| Price | $2.99 | $5.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 106.5K | ★ 407.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $3.20 |
| 52 Week High | $3.88 | $7.92 |
| Indicator | VOC | CING |
|---|---|---|
| Relative Strength Index (RSI) | 53.59 | 49.24 |
| Support Level | $2.79 | $5.47 |
| Resistance Level | $3.29 | $7.92 |
| Average True Range (ATR) | 0.13 | 0.68 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 54.88 | 12.65 |
VOC Energy Trust is a statutory trust. It is created to acquire and hold a term net profits interest for the benefit of the Trust unitholders. The underlying properties include VOC Brazos' net interests which are located in the states of Kansas and Texas. The trust is entitled to receive the net proceeds from the sale of production of oil and natural gas attributable to the underlying properties. The business and affairs of the Trust are managed by the Trustee, and neither VOC Brazos nor any of its affiliates has the ability to manage or influence the operations of the Trust.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.